Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Breast Cancer Clinical Trial

— BRIA-ABC  

Official title:

Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06072612
• Other study ID #: BC-IMT-04
• Status: Recruiting
• Phase: Phase 3
• Start date: December 5, 2023
• Est. completion date: December 2025

Study information

• Verified date: June 2024
• Source: BriaCell Therapeutics Corporation
• Contact: Maggie Tomasini, CPM
• Phone: 267-946-7346
• Email: Maggie.Tomasini[@]PrevailinfoWorks.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor [Retifanlimab], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies available.

Description:

This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor [Retifanlimab], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies available. A secondary objective will be to evaluate the activity of the Bria-IMT regimen alone in comparison with the Bria-IMT regimen in combination with CPI.

Initial randomization will be 1:1:1 to the Bria-IMT regimen + CPI (combination therapy), TPC, and the Bria-IMT regimen alone (monotherapy). After the first 150 patients have enrolled in the study, the monotherapy arm will be discontinued and patients allowed to cross over to the combination therapy if needed. Randomization will continue 1:1 between the combination therapy vs TPC.

For the Bria regimen +/- CPI arms, treatment cycles occur every 3 weeks. TPC cycle details will be according to the site's SOC. In the absence of progressive disease or major safety issues, the patient will continue with therapy cycles, with imaging assessment every 6 weeks x2 then every 8 weeks thereafter.

The Bria-IMT regimen includes:

Day -2 or -3 Cyclophosphamide 300mg/m2 Day 0 SV-BR-1-GM given intradermally divided into 4 inoculations Day 1-3 CPI infusion plus interferon intra-dermally within each Bria-IMT inoculation site

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 404
• Est. completion date: December 2025
• Est. primary completion date: June 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Be = 18 years of age.

2. Have signed informed consent.

3. Have histological confirmation of breast cancer with either locally recurrent unresectable and/or metastatic lesions, and have failed prior therapy:

• Patients with persistent disease and local recurrence must not be amenable to local treatment.

• For patients with metastatic disease, late-stage MBC with no meaningful alternative therapies available and the following class specific treatment histories:

1. Human epidermal growth factor 2 (HER2) positive must be previously treated with at least 3 regimens containing at least two anti-HER2 and at least one chemotherapy containing regimen.

2. Estrogen receptor (ER), progesterone receptor (PR) positive tumors: must be refractory to hormonal therapy demonstrated by progression on at least 2 hormonal agents in 2 separate lines of hormone directed therapy.

3. Triple Negative tumors: Must have exhausted all curative intent therapies including at least 2 prior chemotherapy regimens, which can include regimens in neoadjuvant and adjuvant settings.

4. Cancers with known germline or genomic actionable targets, e.g. g/mBRCA, must have been treated with all tumor directed indicated treatment e.g. PARPi, if tolerated.

5. HER2 low patients, in addition to the appropriate therapies based on ER/PR status and germline or genomic actionable targets, must also have received at least one HER2-targeted agent approved for treatment of HER2 low patients.

6. HER2 negative tumors must be refractory to hormonal therapy (if indicated) and previously treated with at least 2 chemotherapy regimens.

7. Patients with new or progressive breast cancer metastatic to the brain will be eligible provided:

• The brain metastases must be clinically stable (without evidence of progressive disease by imaging for at least 4 weeks prior to first dose)

• There is no need for steroids and patients have not had steroids for at least 2 weeks prior to the first dose

• Tumor is not impinging on Middle Cerebral Artery/speech-motor strip

• If surgically debulked, must be healed with at least 3 weeks since surgery prior to the first dose

4. Has expected survival of at least 4 months.

5. ECOG performance status of 0, 1 or 2

Exclusion Criteria:

1. Concurrent or recent chemotherapy, immunotherapy or major surgery within 21 days prior to the first dose.

2. Radiotherapy within 14 days of the first dose of study treatment.

3. Toxicity of prior therapy that has not recovered to = Grade 1 or baseline (with the exception of any grade of alopecia and anemia not requiring transfusion support).

4. Any toxicity to prior CPI that was grade 3 or higher unless it has been successfully treated (e.g. hypothyroidism or hypopituitarism treated with replacement therapy), .

5. Toxicity to prior CPI that has not resolved to grade 1 or less except for stable asymptomatic endocrinopathies.

6. History of clinical hypersensitivity to the designated therapy as specified in the protocol, including the proposed TPC, beef, or to any components used in the preparation of SV- BR-1-GM.

7. History of hypersensitivity to any of the therapies proposed for treatment in this study.

8. Serum creatinine OR Measured OR calculated Creatinine Clearance (CrCl) (GFR can also be used in place of creatinine or CrCl) >2.0 × ULN or <30 mL/min for participants with creatinine levels >2.0 × institutional ULN.

9. Absolute granulocyte count <1000; platelets <80,000; hemoglobin = 7 g/L.

10. Bilirubin = 2 × ULN unless conjugated bilirubin = ULN; alkaline phosphatase >5x upper limit of normal (ULN); ALT/AST >3x ULN. For patients with hepatic metastases, ALT/AST >5x ULN is exclusionary.

11. INR or PT or aPTT > 1.8 × ULN, unless the participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants.

12. Receiving any medication listed in the prohibited medication section of the protocol.

13. Proteinuria >2+ on urinalysis

14. A history or presence of an abnormal electrocardiogram (ECG) that, in the Investigator's opinion, is clinically meaningful. Screening corrected QT interval (QTc) interval >480 milliseconds is excluded (corrected by Fridericia or Bazett formula). In the event that a single QTc is >480 milliseconds, the participant may enroll if the average QTc for the 3 ECGs is <480 milliseconds.

15. New York Heart Association stage 3 or 4 cardiac disease.

16. A pericardial effusion of moderate severity or worse.

17. Symptomatic pleural effusion or ascites. A participant who is clinically stable following treatment for these conditions (including therapeutic thoraco- or paracentesis) is eligible.

18. Any woman of childbearing potential (i.e., has had a menstrual cycle within the past year and has not been surgically sterilized), unless she agrees to take appropriate precautions to avoid becoming pregnant during the study and has a negative serum pregnancy test within 7 days prior to starting treatment.

19. Men must have been sterile or, if they were potentially fertile/reproductively competent, should take appropriate precautions to avoid fathering a child for the duration of the study.

20. Women who are pregnant or nursing.

21. Known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years of study entry with the exception of cured basal cell or squamous cell carcinoma of the skin, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other noninvasive or indolent malignancy, or cancers from which the participant has been disease-free for > 1 year, after treatment with curative intent.

22. Patients who have uncontrolled HIV or have clinical or laboratory features indicative of AIDS.

23. Have a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (doses exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment.

24. Have an active autoimmune disease that has required systemic treatment in past year (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is allowed.

25. Known active HAV, HBV, or HCV infection, as defined by elevated transaminases with the following serology: positivity for HAV IgM antibody, anti-HCV, anti-HBc IgG or IgM, or HBsAg (in the absence of prior immunization).

26. Active infections requiring systemic therapy within the past 14 days.

27. Patients with severe psychiatric disease (e.g., schizophrenia, bipolar, or borderline personality disorder) or other clinically progressive major medical problems, unless approved by the Investigator in consultation with the Medical Monitor.

28. Has received a live vaccine within 28 days of the first dose of study drug.

29. Patients may not be on a concurrent clinical trial, unless approved by the Investigator.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Cancer Metastatic
• Breast Neoplasm
• Breast Neoplasms
• End Stage Cancer
• Metastatic Breast Cancer

Intervention

Biological:
• SV-BR-1-GM
SV-BR-1-GM is an experimental, allogeneic, whole cell breast tumor cell line stably transfected with the CSF2 gene (encoding GM-CSF) to secrete GM-CSF in vivo to consequently augment dendritic cell activity

Drug:
• Cyclophosphamide
Cyclophosphamide is an alkylating agent with indications for treatment of malignant diseases including breast cancer. Cyclophosphamide (Cytoxan) 300 mg/m2 I.V., single dose, will be given to patients assigned to the SV-BR-1-GM. Cyclophosphamide will be administered 2-3 days prior to SV-BR-1-GM inoculations.
• Interferon infiltration of the inoculation site
Interferon is a cytokine released by cells to regulate immune responses to viral infections. For this study, 0.1 mcg Pegasys per injection site (x 4 injection sites) will be administered.
• Retifanlimab
Retifanlimab is a checkpoint inhibitor. A total dose of 375mg will be administered at first cycle on or about day +2 (+/-1d). In all other cycles, Retifanlimab is permitted to be administered between Day -2/-3 to Day 2±1 of the cycle based on the convenience of the patients and the clinical sites. However once the timing of the CPI is chosen for C1, it must be given on the same day thereafter throughout the trial.
• Treatment of Physician's Choice
Patients in the TPC arm of the study will be treated with one or a combination of the following: carboplatin, taxanes, capecitabine, gemcitabine, vinorelbine or eribulin in accordance with the investigators and institutional standard of care. For HER2+ patients, a HER2-targeted agent of the physician's choice can be part of TPC.

Locations

Country	Name	City	State
United States	The Center for Cancer and Blood Disorders a division of American Oncology Partners, P.A.	Bethesda	Maryland
United States	Gabrail Cancer & Research Center	Canton	Ohio
United States	Mary Crowley Cancer Research	Dallas	Texas
United States	Texas Oncology-Baylor Charles A. Sammons Cancer Center	Dallas	Texas
United States	Hematology-Oncology Associates of Fredericksburg, Inc	Fredericksburg	Virginia
United States	AMR Kansas City Oncology	Kansas City	Kansas
United States	Care Access-Marrero	Marrero	Louisiana
United States	Nebraska Cancer Specialists	Omaha	Nebraska
United States	Advent Health - Orlando	Orlando	Florida
United States	New York Cancers & Blood Specialists	Port Jefferson Station	New York
United States	Texas Oncology-San Antonio Cancer Care	San Antonio	Texas
United States	Cancer Care Northwest	Spokane Valley	Washington
United States	Tranquil Clinical Research	Webster	Texas

Sponsors (1)

Lead Sponsor	Collaborator
BriaCell Therapeutics Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Survival	To evaluate the effect of the Bria-IMT regimen in combination with Check Point Inhibitor (CPI) on overall survival (OS) compared to treatment of physician's choice (TPC) chemotherapy in patients with metastatic breast cancer with no approved alternative therapies available as per the Inclusion criteria.	Up to 60 months
Secondary	Progression-free survival (PFS)	To evaluate the effect of the Bria-IMT regimen with CPI on progression-free survival (PFS); • To assess the single agent activity of the Bria-IMT regimen in the sample cohort using PFS, ORR, and CBR	Up to 60 months
Secondary	Clinical Benefit Rate (CBR)	To evaluate the efficacy of the Bria-IMT regimen with CPI using Clinical Benefit Rate (CBR)	Up to 60 months
Secondary	Overall response rate (ORR)	To evaluate the efficacy of the Bria-IMT regimen with CPI using best overall response rate (ORR)	Up to 60 months
Secondary	Quality of life (QoL)	To compare the effect of the Bria-IMT regimen with CPI on quality of life (QoL) including time without symptoms and time without toxicities (TWiST) adjusted for time on study.	Up to 60 months
Secondary	CNS Event free survival (EFS)	CNS event free survival for subjects with and without known CNS metastases at baseline	Up to 60 months

External Links

•   CRO
•   Sponsor